145 related articles for article (PubMed ID: 16118711)
1. Recent advances in JAK3 kinase inhibitors.
Sudbeck EA; Uckun FM
IDrugs; 1999 Oct; 2(10):1026-30. PubMed ID: 16118711
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.
Sudbeck EA; Liu XP; Narla RK; Mahajan S; Ghosh S; Mao C; Uckun FM
Clin Cancer Res; 1999 Jun; 5(6):1569-82. PubMed ID: 10389946
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the antigen-induced activation of rodent mast cells by putative Janus kinase 3 inhibitors WHI-P131 and WHI-P154 in a Janus kinase 3-independent manner.
Linwong W; Hirasawa N; Aoyama S; Hamada H; Saito T; Ohuchi K
Br J Pharmacol; 2005 Jul; 145(6):818-28. PubMed ID: 15852029
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic nanoparticle constructs of a JAK3 tyrosine kinase inhibitor against human B-lineage ALL cells.
Uckun FM; Dibirdik I; Qazi S; Yiv S
Arzneimittelforschung; 2010; 60(4):210-7. PubMed ID: 20486472
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of Janus kinase 3 (JAK3) inhibitors.
Cetkovic-Cvrlje M; Tibbles HE
Curr Pharm Des; 2004; 10(15):1767-84. PubMed ID: 15180539
[TBL] [Abstract][Full Text] [Related]
6. Computational analyses of JAK1 kinase domain: subtle changes in the catalytic cleft influence inhibitor specificity.
Zhang X; Hu Y; Yuan Z
Biochem Biophys Res Commun; 2008 May; 370(1):72-6. PubMed ID: 18346458
[TBL] [Abstract][Full Text] [Related]
7. Janus kinase 3 inhibitor WHI-P154 in macrophages activated by bacterial endotoxin: differential effects on the expression of iNOS, COX-2 and TNF-alpha.
Sareila O; Korhonen R; Kärpänniemi O; Nieminen R; Kankaanranta H; Moilanen E
Int Immunopharmacol; 2008 Jan; 8(1):100-8. PubMed ID: 18068105
[TBL] [Abstract][Full Text] [Related]
8. Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis.
Malaviya R; Zhu D; Dibirdik I; Uckun FM
J Biol Chem; 1999 Sep; 274(38):27028-38. PubMed ID: 10480916
[TBL] [Abstract][Full Text] [Related]
9. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains.
Williams NK; Bamert RS; Patel O; Wang C; Walden PM; Wilks AF; Fantino E; Rossjohn J; Lucet IS
J Mol Biol; 2009 Mar; 387(1):219-32. PubMed ID: 19361440
[TBL] [Abstract][Full Text] [Related]
10. In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4'hydroxyphenyl)-amino-6,7- dimethoxyquinazoline.
Uckun FM; Ek O; Liu XP; Chen CL
Clin Cancer Res; 1999 Oct; 5(10):2954-62. PubMed ID: 10537365
[TBL] [Abstract][Full Text] [Related]
11. Recent patents in the discovery of small molecule inhibitors of JAK3.
Wilson LJ
Expert Opin Ther Pat; 2010 May; 20(5):609-23. PubMed ID: 20402545
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of novel anticancer agents.
Uckun FM; Sudbeck EA; Mao C; Ghosh S; Liu XP; Vassilev AO; Navara CS; Narla RK
Curr Cancer Drug Targets; 2001 May; 1(1):59-71. PubMed ID: 12188892
[TBL] [Abstract][Full Text] [Related]
13. In vivo pharmacokinetics and anti-anaphylactic activity of the novel mast cell inhibitor 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131).
Malavija R; Chen CL; Liu XP; Uckun FM
Am J Ther; 2001; 8(1):35-9. PubMed ID: 11304656
[TBL] [Abstract][Full Text] [Related]
14. Quantitative high-performance liquid chromatographic method for pharmacokinetic studies of the potent mast cell inhibitor 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P131).
Chen CL; Malaviya R; Chen H; Liu XP; Uckun FM
J Chromatogr B Biomed Sci Appl; 1999 Apr; 727(1-2):205-12. PubMed ID: 10360439
[TBL] [Abstract][Full Text] [Related]
15. Oncostatin M promotes osteogenesis and suppresses adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells.
Song HY; Jeon ES; Kim JI; Jung JS; Kim JH
J Cell Biochem; 2007 Aug; 101(5):1238-51. PubMed ID: 17226768
[TBL] [Abstract][Full Text] [Related]
16. JAK pathway induction of c-Myc critical to IL-5 stimulation of cell proliferation and inhibition of apoptosis.
Lee WH; Liu FH; Lin JY; Huang SY; Lin H; Liao WJ; Huang HM
J Cell Biochem; 2009 Apr; 106(5):929-36. PubMed ID: 19180571
[TBL] [Abstract][Full Text] [Related]
17. Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting.
Cassinelli G; Ronchetti D; Laccabue D; Mattioli M; Cuccuru G; Favini E; Nicolini V; Greco A; Neri A; Zunino F; Lanzi C
Biochem Pharmacol; 2009 Nov; 78(9):1139-47. PubMed ID: 19555670
[TBL] [Abstract][Full Text] [Related]
18. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
19. Prodigiosins: a novel family of immunosuppressants with anti-cancer activity.
Pandey R; Chander R; Sainis KB
Indian J Biochem Biophys; 2007 Oct; 44(5):295-302. PubMed ID: 18341204
[TBL] [Abstract][Full Text] [Related]
20. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.
Duan Z; Bradner J; Greenberg E; Mazitschek R; Foster R; Mahoney J; Seiden MV
Mol Pharmacol; 2007 Nov; 72(5):1137-45. PubMed ID: 17675586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
